Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Staar Sets Sights On ICL Approval, Awaits Swiss, U.S. Facility Inspections

This article was originally published in The Gray Sheet

Executive Summary

Staar Surgical expects to launch the Visian ICL intraocular lens at the American Academy of Ophthalmology's October annual meeting, barring further approval setbacks resulting from FDA inspections

You may also be interested in...



Staar Compliance Effort Exempt From Belt Tightening; Merger Among Options

Staar Surgical will seek to raise $8 mil.-$10 mil. from existing investors to shore up its cash position while it considers strategic alternatives, including a possible sale of the company, the firm says

Staar Compliance Effort Exempt From Belt Tightening; Merger Among Options

Staar Surgical will seek to raise $8 mil.-$10 mil. from existing investors to shore up its cash position while it considers strategic alternatives, including a possible sale of the company, the firm says

AMO To Surround Eye Surgeons With Refractive Offerings After Visx Purchase

Advanced Medical Optics' acquisition of pure-play LASIK manufacturer Visx will enable the combined entity to more effectively market laser eye surgery to physicians performing both refractive and cataract procedures

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020208

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel